Expanded treatment options for opioid use disorder (OUD) are needed to promote long-term recovery in more patients. The Helping to End Addiction Long-termSM Initiative, or NIH HEAL InitiativeSM, will accelerate the development of novel medications and devices to treat all aspects of the opioid addiction cycle, including progression to chronic use, withdrawal symptoms, craving, relapse, and overdose.

Research Programs

To comprehensively address opioid addiction, the NIH HEAL Initiative will support the development of new formulations of existing medications to treat OUD; longer-duration formulations to counteract opioid overdose; interventions for respiratory depression; and novel medications to treat progression to chronic use, withdrawal, craving, and relapse.

The NIH HEAL Initiative will support the creation of a coordinated, multidisciplinary consortium to develop anti-opioid vaccines and test them in clinical trials. These vaccines will induce antibodies that bind specifically to target opioids, reducing their effects and offering protection from overdose.

Funded Projects

2020
PHASE 1A/1B CLINICAL TRIALS OF MULTIVALENT OPIOID VACCINE COMPONENTS
Mar 19, 2020
2020
Cannabidiol in the treatment of opioid use disorder
Mar 19, 2020
2020
Combined tDCS and Cognitive Training for the Treatment of Opioid Addiction
Mar 19, 2020
2019
1-Year Sustained Release Naltrexone Implant for the prevention of relapse to opioid dependence
Sep 25, 2019
2020
Web-Based Treatment for Perinatal Opioid Use Disorder
Mar 19, 2020

Closed Funding Opportunities

2019
Behavioral & Integrative Treatment Development Program (R01 Clinical Trial Optional)
Sep 25, 2019
2019
NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
Sep 25, 2019
2019
NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
Sep 25, 2019
2019
NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
Sep 25, 2019
2019
Strategic Alliances for Medications Development to Treat Substance Use Disorders (R01 Clinical Trial Optional)
Sep 25, 2019